Cost-effectiveness evaluation to inform clinical trial design

Editorial

Heather J Ribaudo. Clin Infect Dis. 2007.

. 2007 Oct 15;45(8):1071-3.

doi: 10.1086/521934. Epub 2007 Sep 4.

No abstract available

Comment on

Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Schackman BR, et al. Clin Infect Dis. 2007 Oct 15;45(8):1062-70. doi: 10.1086/521933. Epub 2007 Sep 4. Clin Infect Dis. 2007. PMID: 17879926 Free PMC article.

Cost-effectiveness of HIV therapies in different economic worlds.
Laurence J. Laurence J. AIDS Read. 2001 May;11(5):236-7. AIDS Read. 2001. PMID: 11392685 No abstract available.
Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD. Desai K, et al. AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5. AIDS. 2008. PMID: 18753932
[Just expensive or also cost effective? Pharmacoeconomic aspects of HIV therapy].
Glaeske G. Glaeske G. Pharm Unserer Zeit. 2001;30(3):248-52. doi: 10.1002/1615-1003(200105)30:3<248::AID-PAUZ248>3.0.CO;2-9. Pharm Unserer Zeit. 2001. PMID: 11400675 Review. German. No abstract available.
CD4 count most cost-effective.
[No authors listed] [No authors listed] AIDS Patient Care STDS. 2006 Sep;20(9):658. AIDS Patient Care STDS. 2006. PMID: 17039590 No abstract available.
Designing and interpreting HIV noninferiority trials in naive and experienced patients.
Hill A, Sabin C. Hill A, et al. AIDS. 2008 May 11;22(8):913-21. doi: 10.1097/QAD.0b013e3282f5556d. AIDS. 2008. PMID: 18453850 Review. No abstract available.